In vitro dissolution testing of drug-eluting stents

Current Pharmaceutical Biotechnology

Volumn 14, Issue 1, 2013, Pages 67-75

  Seidlitz, Anne ^a   Nagel, Stefan ^a   Semmling, Beatrice ^a   Sternberg, Katrin ^b   Kroemer, Heyo K ^a   Weitschies, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Biorelevant dissolution; Drug eluting stent; Flow through cell; In vitro dissolution; Reciprocating holder; Vesselsimulating flow through cell

Indexed keywords

EVEROLIMUS; PACLITAXEL; PHOSPHATE BUFFERED SALINE; RAPAMYCIN; SODIUM CHLORIDE;

APPARATUS; ARTICLE; DISSOLUTION; DRUG ELUTING STENT; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; MECHANICAL STRESS; MEDICAL LITERATURE; NONHUMAN; PRACTICE GUIDELINE; STENT; TEMPERATURE;

ANIMALS; DRUG-ELUTING STENTS; EQUIPMENT SAFETY; HUMANS; MATERIALS TESTING; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84872535799     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920113804805403     Document Type: Article

References (89)

1. Palmaz, J.C.; Richter, G.M.; Noldge, G.; Kauffmann, G.W.; Wenz, W. Intraluminal Palmaz stent implantation. The first clinical case report on a balloon-expanded vascular prosthesis. Radiologe, 1987, 27(12), 560-563.
2. Nikolsky, E.; Mehran, R.; Ashby, D.T.; Dangas, G. D; Lansky, A.J.; Stone, G.W.; Moses, J.W.; Leon, M.B. Restenosis following percu taneous coronary interventions: a clinical problem. In: Handbook of drug-eluting Stents; Serruys, P.W.; Gerschlick, A.H. Eds., Taylor and Francis: London, 2005; pp. 3-14.
3. Carter, A.J.; Tsao, P. Histophathology of restenosis. In: Handbook of drug-eluting Stents; Serruys, P.W.; Gerschlick, A.H. Eds., Taylor and Francis: London, 2005; pp. 15-24.
4. Acharya, G.; Park, K. Mechanisms of controlled drug release from drug-eluting stents. Adv. Drug Deliv. Rev., 2006, 58(3), 387-401.
5. Tada, N.; Virmani, R.; Grant, G.; Bartlett, L.; Black, A.; Clavijo, C.; Christians, U.; Betts, R.; Savage, D.; Su, S.H.; Shulze, J.; Kar, S. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ. Cardiovasc. Interv., 2010, 3(2), 174-183.
6. Steigerwald, K.; Merl, S.; Kastrati, A.; Wieczorek, A.; Vorpahl, M.; Mannhold, R.; Vogeser, M.; Hausleiter, J.; Joner, M.; Schomig, A.; Wessely, R. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials, 2009, 30(4), 632-637.
7. Hausleiter, J.; Kastrati, A.; Wessely, R.; Dibra, A.; Mehilli, J.; Schratzenstaller, T.; Graf, I.; Renke-Gluszko, M.; Behnisch, B.; Dirschinger, J.; Wintermantel, E.; Schomig, A. Prevention of restenosis by a novel drug-eluting stent system with a doseadjustable, polymer-free, on-site stent coating. Eur. Heart J., 2005, 26(15), 1475-1481.
8. Moses, J.W.; Leon, M.B.; Popma, J.J.; Fitzgerald, P.J.; Holmes, D.R.; O'Shaughnessy, C.; Caputo, R.P.; Kereiakes, D.J.; Williams, D.O.; Teirstein, P.S.; Jaeger, J.L.; Kuntz, R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med., 2003, 349(14), 1315-1323.
9. Stone, G.W.; Ellis, S.G.; Cox, D.A.; Hermiller, J.; O'Shaughnessy, C.; Mann, J.T.; Turco, M.; Caputo, R.; Bergin, P.; Greenberg, J.; Popma, J.J.; Russell, M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med., 2004, 350(3), 221-231.
10. Stone, G.W. Coronary Stenting. In: Grossman's cardiac catheterization, angiography, and intervention. Baim, D.S. Ed.; Lippincott Williams & Wilkins: Philadelphia, 2006; pp. 492-542.
11. Morice, M.C.; Serruys, P.W.; Sousa, J.E.; Fajadet, J.; Ban Hayashi, E.; Perin, M.; Colombo, A.; Schuler, G.; Barragan, P.; Guagliumi, G.; Molnar, F.; Falotico, R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med., 2002, 346(23), 1773-1780.
12. Klugherz, B.D.; Llanos, G.; Lieuallen, W.; Kopia, G.A.; Papandreou, G.; Narayan, P.; Sasseen, B.; Adelman, S.J.; Falotico, R.; Wilensky, R.L. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron. Artery Dis., 2002, 13(3), 183-188.
13. Camenzind, E.; Steg, P.G.; Wijns, W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation, 2007, 115(11), 1440-1455.
14. Nordmann, A.J.; Briel, M.; Bucher, H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J., 2006, 27(23), 2784-2814.
15. Garg, S.; Serruys, P.W. Drug-eluting stents: a reappraisal. Heart, 2010, 96(7), 489-493.
16. Puskas, J.E.; Munoz-Robledo, L.G.; Hoerr, R.A.; Foley, J.; Schmidt, S.P.; Evancho-Chapman, M.; Dong, J.; Frethem, C.; Haugstad, G. Drug-eluting stent coatings. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1(4), 451-462.
17. Cutlip, D.E.; Windecker, S.; Mehran, R.; Boam, A.; Cohen, D.J.; van Es, G.A.; Steg, P.G.; Morel, M.A.; Mauri, L.; Vranckx, P.; McFadden, E.; Lansky, A.; Hamon, M.; Krucoff, M.W.; Serruys, P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007, 115(17), 2344-2351.
18. Windecker, S.; Meier, B. Late coronary stent thrombosis. Circulation, 2007, 116(17), 1952-1965.
19. Daemen, J.; Wenaweser, P.; Tsuchida, K.; Abrecht, L.; Vaina, S.; Morger, C.; Kukreja, N.; Juni, P.; Sianos, G.; Hellige, G.; van Domburg, R.T.; Hess, O.M.; Boersma, E.; Meier, B.; Windecker, S.; Serruys, P.W. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007, 369(9562), 667-678.
20. Venkatraman, S.; Boey, F. Release profiles in drug-eluting stents: issues and uncertainties. J. Control. Release, 2007, 120(3), 149-160.
21. Lansky, A.J.; Costa, R.A.; Mintz, G.S.; Tsuchiya, Y.; Midei, M.; Cox, D.A.; O'Shaughnessy, C.; Applegate, R.A.; Cannon, L.A.; Mooney, M.; Farah, A.; Tannenbaum, M.A.; Yakubov, S.; Kereiakes, D.J.; Wong, S.C.; Kaplan, B.; Cristea, E.; Stone, G.W.; Leon, M.B.; Knopf, W.D.; O'Neill, W.W. Non-polymer-based paclitaxelcoated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation, 2004, 109(16), 1948-1954.
22. Serruys, P.W.; Sianos, G.; Abizaid, A.; Aoki, J.; den Heijer, P.; Bonnier, H.; Smits, P.; McClean, D.; Verheye, S.; Belardi, J.; Condado, J.; Pieper, M.; Gambone, L.; Bressers, M.; Symons, J.; Sousa, E.; Litvack, F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J. Am. Coll. Cardiol., 2005, 46(2), 253-260.
23. Scheller, B.; Hehrlein, C.; Bocksch, W.; Rutsch, W.; Haghi, D.; Dietz, U.; Bohm, M.; Speck, U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med., 2006, 355(20), 2113-2124.
24. Axel, D.I.; Kunert, W.; Goggelmann, C.; Oberhoff, M.; Herdeg, C.; Kuttner, A.; Wild, D.H.; Brehm, B.R.; Riessen, R.; Koveker, G.; Karsch, K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 1997, 96(2), 636-645.
25. Hwang, C.W.; Wu, D.; Edelman, E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation, 2001, 104(5), 600-605.
26. Vetrovec, G.W.; Rizik, D.; Williard, C.; Snead, D.; Piotrovski, V.; Kopia, G. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc. Interv., 2006, 67(1), 32-37.
27. Wang, Q.; Pierson, W.; Sood, P.; Bol, C.; Cannon, L.; Gordon, P.; Saucedo, J.; Sudhir, K. Pharmacokinetic sub-study in the SPIRIT III randomized and controlled trial of XIENCE V everolimus eluting coronary stent system. J. Interv. Cardiol., 2009, 23(1), 26-32.
28. Perkins, L.E.L.; Boeke-Purkis, K.H.; Wang, Q.; Stringer, S.K.; Coleman, L.A. XIENCE V everolimus-eluting coronary stent system: A preclinical assessment. J. Interv. Cardiol., 2009, 22(1), 28-40.
29. Kamath, K.R.; Barry, J.J.; Miller, K.M. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv. Drug Deliv. Rev., 2006, 58(3), 412-436.
30. Carter, A.J.; Aggarwal, M.; Kopia, G.A.; Tio, F.; Tsao, P.S.; Kolata, R.; Yeung, A.C.; Llanos, G.; Dooley, J.; Falotico, R. Longterm effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res., 2004, 63(4), 617-624.
31. European Medicines Agency-Committee for Medicinal Products for Human Use. Guideline on the clinical and non clinical evaluation during the consultation procedure on medicinal substances contained in drug-eluting (medicinal substance-eluting) coronary stents. London, 2008.
32. Food and Drug Administration. Draft-guidance for industry, coronary drug-eluting stents-nonclinical and clinical studies. Rockville, 2008.
33. Schwartz, R.S.; Edelman, E.R.; Carter, A.; Chronos, N.; Rogers, C.; Robinson, K.A.; Waksman, R.; Weinberger, J.; Wilensky, R.L.; Jensen, D.N.; Zuckerman, B.D.; Virmani, R. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation, 2002, 106(14), 1867-1873.
34. Burgess, D.J.; Crommelin, D.J.; Hussain, A.S.; Chen, M.L. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci., 2004, 6(1), E11.
35. Boden, M.; Richard, R.; Schwarz, M.C.; Kangas, S.; Huibregtse, B.; Barry, J.J. In vitro and in vivo evaluation of the safety and stability of the TAXUS Paclitaxel-Eluting Coronary Stent. J. Mater. Sci. Mater. Med., 2009, 20(7), 1553-1562.
36. Schmidt, W.; Lanzer, P.; Behrens, P.; Topoleski, L.D.; Schmitz, K.P. A comparison of the mechanical performance characteristics of seven drug-eluting stent systems. Catheter Cardiovasc. Interv., 2009, 73(3), 350-360.
37. Tepe, G.; Schmehl, J.; Wendel, H.P.; Schaffner, S.; Heller, S.; Gianotti, M.; Claussen, C.D.; Duda, S.H. Reduced thrombogenicity of nitinol stents-in vitro evaluation of different surface modifications and coatings. Biomaterials, 2006, 27(4), 643-650.
38. Kolandaivelu, K.; Edelman, E.R. Low background, pulsatile, in vitro flow circuit for modeling coronary implant thrombosis. J. Biomech. Eng., 2002, 124(6), 662-668.
39. Nowak, B.; Meyer, J.M.; Goergen, T.; Fluehs, D.; Block, S.; Guenther, R.W.; Hoecker, H.; Buell, U. Dosimetry of a 188rheniumlabeled self-expanding stent for endovascular brachytherapy in peripheral arteries. Cardiovasc. Radiat. Med., 2001, 2(4), 246-253.
40. Sharkawi, T.; Leyni-Barbaz, D.; Chikh, N.; McMullen, J.N. Evaluation of the in vitro drug release from resorbable biocompatible coatings for vascular stents. J. Bioact. Compat. Polym., 2005, 20(2), 153-168.
41. Lao, L.L.; Venkatraman, S.S. Adjustable paclitaxel release kinetics and its efficacy to inhibit smooth muscle cells proliferation. J. Control. Release, 2008, 130(1), 9-14.
42. Gagliardi, M.; Silvestri, D.; Cristallini, C.; Guadagni, M.; Crifaci, G.; Giusti, P. Combined drug release from biodegradable bilayer coating for endovascular stents. J. Biomed. Mater. Res. B Appl. Biomater., 2010, 93(2), 375-385.
43. Seidlitz, A.; Nagel, S.; Semmling, B.; Grabow, N.; Martin, H.; Senz, V.; Harder, C.; Sternberg, K.; Schmitz, K.-P.; Kroemer, H.K.; Weitschies, W. Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flow-through cell. Eur. J. Pharm. Biopharm., 2011, 78(1),36-48.
44. Sternberg, K.; Kramer, S.; Nischan, C.; Grabow, N.; Langer, T.; Hennighausen, G.; Schmitz, K.P. In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A-drug release, polymer degradation and mechanical integrity. J. Mater. Sci. Mater. Med., 2007, 18(7), 1423-1432.
45. Kamberi, M.; Nayak, S.; Myo-Min, K.; Carter, T.P.; Hancock, L.; Feder, D. A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: Insight to the drug release mechanisms. Eur. J. Pharm. Sci., 2009, 37(3-4), 217-222.
46. Lockwood, N.A.; Hergenrother, R.W.; Patrick, L.M.; Stucke, S.M.; Steendam, R.; Pacheco, E.; Virmani, R.; Kolodgie, F.D.; Hubbard, B. In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings. J. Biomater. Sci. Polym. Ed., 2010, 21(4), 529-552.
47. Hopkins, C.G.; McHugh, P.E.; McGarry, J.P. Computational Investigation of the Delamination of Polymer Coatings During Stent Deployment. Ann. Biomed. Eng., 2010, 38(7), 2263-2273.
48. Mani, G.; Feldman, M.D.; Patel, D.; Agrawal, C.M. Coronary stents: a materials perspective. Biomaterials, 2007, 28(9), 1689-1710.
49. Huang, Y.; Salu, K.; Liu, X.; Li, S.; Wang, L.; Verbeken, E.; Bosmans, J.; De Scheerder, I. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart, 2004, 90(2), 195-199.
50. Park, T.G.; Lu, W.; Crotts, G. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D, L-lactic acid-co-glycolic acid) microspheres. J. Control. Release, 1995, 33(2), 211-222.
51. Jantratid, E.; Janssen, N.; Reppas, C.;, Dressman, J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res., 2008, 25(7),1663-1676.
52. Diakidou, A.; Vertzoni, M.; Dressman, J.; Reppas, C. Estimation of intragastric drug solubility in the fed state: comparison of various media with data in aspirates. Biopharm. Drug Dispos., 2009, 30(6), 318-325.
53. Minghetti, P.; Cilurzo, F.; Selmin, F.; Casiraghi, A.; Grignani, A.; Montanari, L. Sculptured drug-eluting stent for the on-site delivery of tacrolimus. Eur. J. Pharm. Biopharm., 2009, 73(3), 331-336.
54. Levin, A.D.; Vukmirovic, N.; Hwang, C.W.; Edelman, E.R. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl. Acad. Sci. USA, 2004, 101(25), 9463-9467.
55. Levin, A.D.; Jonas, M.; Hwang, C.W.; Edelman, E.R. Local and systemic drug competition in drug-eluting stent tissue deposition properties. J. Control. Release, 2005, 109(1-3), 236-243.
56. Tzafriri, A.R.; Vukmirovic, N.; Kolachalama, V.B.; Astafieva, I.; Edelman, E.R. Lesion complexity determines arterial drug distribution after local drug delivery. J. Control. Release, 2010, 142(3), 332-338.
57. Liggins, R.T.; Hunter, W.L.; Burt, H.M. Solid-state characterization of paclitaxel. J. Pharm. Sci., 1997, 86(12), 1458-1463.
58. Simamora, P.; Alvarez, J.M.; Yalkowsky, S.H. Solubilization of rapamycin. Int. J. Pharm., 2001, 213(1-2), 25-29.
59. Raval, A.; Parikh, J.; Engineer, C. Dexamethasone eluting biodegradable polymeric matrix coated stent for intravascular drug delivery. Chem. Eng. Res. Des., 2010, 88(11), 1479-1484.
60. Guo, Q.; Knight, P.T.; Mather, P.T. Tailored drug release from biodegradable stent coatings based on hybrid polyurethanes. J. Control. Release, 2009, 137(3), 224-233.
61. Ranade, S.V.; Miller, K.M.; Richard, R.E.; Chan, A.K.; Allen, M.J.; Helmus, M.N. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J. Biomed. Mater. Res. A, 2004, 71(4), 625-634.
62. Sirianni, R.W.; Jang, E.H.; Miller, K.M.; Saltzman, W.M. Parameter estimation methodology in a model of hydrophobic drug release from a polymer coating. J. Control. Release, 2010, 142(3), 474-482.
63. Pan, C.J.; Tang, J.J.; Weng, Y.J.; Wang, J.; Huang, N. Preparation and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents. Colloids Surf. B Biointerfaces, 2009, 73(2), 199-206.
64. Levy, Y.; Tal, N.; Tzemach, G.; Weinberger, J.; Domb, A.J.; Mandler, D. Drug-Eluting stent with improved durability and controllability properties, obtained via electrocoated adhesive promotion layer. J. Biomed. Mater. Res. B Appl. Biomater., 2009, 91B, 819-830.
65. Tailor, J.; Raval, A.; Engineer, C.; Kotadia, H.; Kothwala, D. Development and validation of a reversed-phase HPLC method for invitro loading and release analysis of paclitaxel coated stent. Trends Biomater. Artif. Organs, 2008, 22(2), 79-86.
66. Nelson, F.C.; Stachel, S.J.; Eng, C.P.; Seghal, S.N. Manipulation of the C(22)-C(27) region of rapamycin: stability issues and biological implications. Bioorg. Med. Chem. Lett., 1999, 9, 295-300.
67. Wang, X.; Venkatraman, S.S.; Boey, F.Y.; Loo, J.S.; Tan, L.P. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials, 2006, 27(32), 5588-5595.
68. Naseerali, C.P.; Hari, P.R.; Sreenivasan, K. The release kinetics of drug eluting stents containing sirolimus as coated drug: Role of release media. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2010, 878, 709-712.
69. Dordunoo, S.K.; Burt, H.M. Solubility and stability of taxol: effects of buffers and cyclodextrins. Int. J. Pharm., 1996, 133, 191-201.
70. United States Phamacopeial Convention Inc. Council of Experts (Ed.). United States Pharmacopeia and National Formulary: Monographs <711> Dissolution, <724> Release. Rockville.
71. Council of Europe (Ed.). European Pharmacopoeia Monographs 2.9.03 dissolution test for solid dosage forms, 2.9.04 dissolution test for transdermal patches. Strassbourg.
72. Brown, W. Apparatus 4 flow though cell: some thoughts on operational characteristics. Dissolution Technol., 2005, 12(2), 28-30.
73. Crist, B. 2009 Trends in small-volume dissolution apparatus for low-dose compounds. Dissolution Technol., 2009, 16(1), 19-22.
74. Martinez, M.N.; Rathbone, M.J.; Burgess, D.; Huynh, M. Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products. J. Control. Release, 2010, 142(1), 2-7.
75. Parker, J.; Gray, V. Highlights of the AAPS workshop on dissolution testing for the 21st century. Dissolution Technol., 2006, 13(3), 26-31.
76. Rajender, G.;. Narayanan, N.G.B. Liquid chromatography-tandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents. Biomed. Chromatogr., 2010, 24, 329-334.
77. Merciadez, M.; Alquier, L.; Mehta, R.; Patel, A.; Wang, A. A novel method for the elution of sirolimus in drug eluting stents. Reference available from: http://www.nikyang.com/pdf/SOTAX/ce7 smart/application/Cordis%20elution%20method.pdf (Accessed April 28, 2010).
78. Looney, T.J. USP Apparatus 4 (flow-through method) primer. Disssolution Technol., 1996, 3(4), 10-12.
79. Di Mario, C.; Meneveau, N.; Gil, R.; de Jaegere, P.; de Feyter, P.J.; Slager, C.J.; Roelandt, J.R.; Serruys, P.W. Maximal blood flow velocity in severe coronary stenoses measured with a Doppler guidewire. Limitations for the application of the continuity equa tion in the assessment of stenosis severity. Am. J. Cardiol., 1993, 71(14), 54D-61D.
80. Wang, G.X.; Luo, L.L.; Yin, T.Y.; Li, Y.; Jiang, T.; Ruan, C.G.; Guidoin, R.; Chen, P.; Guzman, R. Ultrasonic atomization and subsequent desolvation for monoclonal antibody (mAb) to the glycoprotein (GP) IIIa receptor into drug eluting stent. J. Microencapsul., 2010, 27(2), 105-114.
81. Cammarn, S.R.; Sakr, A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution. Int. J. Pharm., 2000, 201(2), 199-209.
82. Morihara, M.; Aoyagi, N.; Kaniwa, N.; Katori, N.; Kojim, S. Hydrodynamic flows around tablets in different pharmacopeial dissolution tests. Drug Dev. Ind. Pharm., 2002, 28(6), 655-662.
83. Neubert, A.; Sternberg, K.; Nagel, S.; Harder, C.; Schmitz, K.P.; Kroemer, H.K.; Weitschies, W. Development of a vesselsimulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. J. Control. Release, 2008, 130(1), 2-8.
84. Zolnik, B.S.; Leary, P.E.; Burgess, D.J. Elevated temperature accelerated release testing of PLGA microspheres. J. Control. Release, 2006, 112(3), 293-300.
85. Li, S.; Girard, A.; Garreau, H.; Vert, M. Enzymatic degradation of polylactide stereocopolymers with predominat D-lactyl contents. Polym. Degrad. Stab., 2001, 71, 61-67.
86. Aso, Y.; Yoshioka, S.; Po, A.L.W.; Terao, T. Effect of temperature on mechanisms of drug release and matrix degradation of poly (D, L-lactide) microspheres. J. Control. Release, 1994, 31(1), 33-39.
87. Makino, K.; Ohshima, H.; Kondo, T. Mechanism of hydrolytic degradation of poly(L-lactide) microcapsules: effects of pH, ionic strength and buffer concentration. J. Microencapsul., 1986, 3(3), 203-212.
88. Agrawal, C.M.; Huang, D.; Schmitz, J.P.; Athanasiou, K.A. Elevated temperature degradion of 50:50 copolymer of PLA-PGA. Tissue Eng., 1997, 3(4), 345-352.
89. Iyer, S.S.; Barr, W.H.; Karnes, H.T. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm. Drug Dispos., 2006, 27(4), 157-170.